X4 Pharmaceuticals (Nasdaq: XFOR) announced the appointment of Kelly Gold to its board of directors, effective July 1, 2026. Gold will serve as an independent director and member of the Audit Committee, according to a press release from the company.

Gold currently serves as Chief Financial Officer at CAMP4 Therapeutics (Nasdaq: CAMP), where she oversees corporate finance and accounting, investor relations, and strategic financial planning. Before becoming CFO at CAMP4, she held roles in business development and finance at the same company.

Prior to CAMP4, Gold held corporate finance and business planning positions at Biogen, where she supported late-stage and marketed rare disease programs. Earlier in her career, she worked in healthcare and Latin American investment banking at Deutsche Bank. Gold began her career as a mechanical engineer designing biocontainment systems for Biosafety Level 4 research facilities.

She holds bachelor's degrees in Biochemistry and Mechanical Engineering from Queen's University in Ontario and an MBA from the MIT Sloan School of Management.

Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals, said Gold "brings a distinct combination of financial leadership, capital markets expertise and a scientific background."

X4 Pharmaceuticals is a rare hematology-focused company headquartered in Boston, Massachusetts. Its drug mavorixafor is approved in the U.S. and EU under the brand name XOLREMDI for patients with WHIM syndrome. The company is currently conducting a Phase 3 clinical trial evaluating mavorixafor in chronic neutropenic disorders.